-
10010400-10An analog of SB203580, the highly specific pyridinylimidazole inhibitor of p38 MAPK inhibits IL-1 production in the human monocytic cell line THP (IC50 = 0.20 µM) and binds CSAID binding protein, a serine/threonine kinase homologous to p38,
-
10010400-25An analog of SB203580, the highly specific pyridinylimidazole inhibitor of p38 MAPK inhibits IL-1 production in the human monocytic cell line THP (IC50 = 0.20 µM) and binds CSAID binding protein, a serine/threonine kinase homologous to p38,
-
10010400-5An analog of SB203580, the highly specific pyridinylimidazole inhibitor of p38 MAPK inhibits IL-1 production in the human monocytic cell line THP (IC50 = 0.20 µM) and binds CSAID binding protein, a serine/threonine kinase homologous to p38,
-
10008846-1A PPAR agonist that displays potent binding at PPAR&alpha, &gamma, and &delta (IC50s = 113, 50, 223 nM, respectively) and potently transactivates PPAR&alpha, &gamma, and &delta (EC50s = 8, 70, 500 nM, respectively) demonstrates stronger
-
10008846-10A PPAR agonist that displays potent binding at PPAR&alpha, &gamma, and &delta (IC50s = 113, 50, 223 nM, respectively) and potently transactivates PPAR&alpha, &gamma, and &delta (EC50s = 8, 70, 500 nM, respectively) demonstrates stronger
-
10008846-5A PPAR agonist that displays potent binding at PPAR&alpha, &gamma, and &delta (IC50s = 113, 50, 223 nM, respectively) and potently transactivates PPAR&alpha, &gamma, and &delta (EC50s = 8, 70, 500 nM, respectively) demonstrates stronger
-
10008846-500A PPAR agonist that displays potent binding at PPAR&alpha, &gamma, and &delta (IC50s = 113, 50, 223 nM, respectively) and potently transactivates PPAR&alpha, &gamma, and &delta (EC50s = 8, 70, 500 nM, respectively) demonstrates stronger
-
10011247-1A potent, selective inhibitor of Cdk9 in vitro (IC50 = 0.35 µM) a competitive inhibitor of Cdk2-cyclin E with respect to ATP, with Ki and IC50 values of 13.3 and 20 µM, respectively.
-
10011247-10A potent, selective inhibitor of Cdk9 in vitro (IC50 = 0.35 µM) a competitive inhibitor of Cdk2-cyclin E with respect to ATP, with Ki and IC50 values of 13.3 and 20 µM, respectively.
-
10011247-5A potent, selective inhibitor of Cdk9 in vitro (IC50 = 0.35 µM) a competitive inhibitor of Cdk2-cyclin E with respect to ATP, with Ki and IC50 values of 13.3 and 20 µM, respectively.
-
10011247-50A potent, selective inhibitor of Cdk9 in vitro (IC50 = 0.35 µM) a competitive inhibitor of Cdk2-cyclin E with respect to ATP, with Ki and IC50 values of 13.3 and 20 µM, respectively.
-
10011248-1A benzimidazole analog that inhibits IKK-&epsilon with an IC50 value of ~15.8 µM.